The Centers for Medicare & Medicaid Services is expected to announce
some key decisions affecting molecular and genetic tests in early September.
The agency is likely to decide that 100+ new molecular CPT codes
will be placed on the Part B clinical lab fee schedule (as opposed to the
Medicare Physician Fee Schedule), according to Bruce Quinn, MD, PhD,
senior health policy specialist at the law firm Foley Hoag LLP. Quinn thinks
pricing will be set near the average or median prices currently charged by
labs using code stacks.
Contact BioMarket Consulting, LLC to understand the impact of this to you business or investments.